Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( JPY)
Sales 2018 255 B
EBIT 2018 -
Net income 2018 41 092 M
Finance 2018 129 B
Yield 2018 1,77%
Sales 2019 273 B
EBIT 2019 -
Net income 2019 46 754 M
Finance 2019 143 B
Yield 2019 1,78%
P/E ratio 2018 34,14
P/E ratio 2019 29,08
EV / Sales2018 5,20x
EV / Sales2019 4,81x
Capitalization 1 455 B
More Financials
Company
Ono Pharmaceutical Co., Ltd. engages in the production, purchase, and sale of pharmaceutical and diagnostic reagents focusing on prescription pharmaceuticals.Its products include respiratory, digestive, urinary, chemotherapy, hormone, vitamins, and metabolic drugs.The company was founded by Ichibei... 
Sector
Pharmaceuticals
Calendar
02/02Earnings Release
More about the company
Surperformance© ratings of ONO PHARMACEUTICAL CO., LT
Trading Rating : Investor Rating :
More Ratings
Latest news on ONO PHARMACEUTICAL CO., LT
01/15 ONO PHARMACEUTICAL : and BMSKK Submit Supplemental Application for Opdivo and Ye..
01/04 ONO PHARMACEUTICAL : New Findings from ONO Pharmaceutical in the Area of Medicin..
2017 ONO PHARMACEUTICAL : Submit Supplemental Application of Opdivo® (Nivolumab) for ..
2017 ONO PHARMACEUTICAL : Submits Supplemental Application of Opdivo® (Nivolumab) for..
2017 ONO PHARMACEUTICAL : Submits Supplemental Application of Opdivo® (Nivolumab) for..
2017 ONO PHARMACEUTICAL : Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivo..
2017 ONO PHARMACEUTICAL : Cyclenium Pharma Announces Drug Discovery Collaboration Agr..
2017 ONO PHARMACEUTICAL : Bristol-Myers Squibb Granted Exclusive License by Ono Pharm..
2017 ONO PHARMACEUTICAL : U.S. Food and Drug Administration (FDA) Accepts Bristol-Mye..
2017 BRISTOL MYERS SQUIBB : Myers teams up with Opdivo maker Ono Pharmaceutical on ne..
More news
Sector news : Generic Pharmaceuticals
01/19 CANADIAN CANNABIS FIRM AURORA IN TAL : sources
01/19 En route to Davos, Macron makes Versailles the place to be
01/19 SHIRE PLC SHIRE PLC : Directorate Change
01/19 At AstraZeneca, fewer drug projects bring big productivity jump
01/18 European shares edge higher as cyclicals back in favour
More sector news : Generic Pharmaceuticals
Latest Tweets
2017ONO PHARMACEUTICAL : Submit Supplemental Application of Opdivo® (Nivolumab) f.. 
2017ONO PHARMACEUTICAL : Submits Supplemental Application of Opdivo® (Nivolumab) .. 
2017Our work with Ono Pharmaceutical aims to explore immuno-suppressive factors i..
3
2017Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O progra.. 
2017We’ve partnered with Ono Pharmaceutical to better understand the potential ro..
6
More tweets
Qtime:33
News from SeekingAlpha
2017 Ono Pharmaceutical Needs To Reinvest Its Windfall
2017 YOUR DAILY PHARMA SCOOP : Axovant's Promised Upside, Gilead's Whistleblower Trou..
2017 Only Bristol Bucks Big Pharma's Drive For External Reliance
2017 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 2, 2017
2017 Array out-licenses binimetinib and encorafenib to Ono Pharma for Japan and So..
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Technical analysis trends ONO PHARMACEUTICAL CO., LT
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 2 917  JPY
Spread / Average Target 8,9%
EPS Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
Sector and Competitors